Opthea Limited
Opthea Limited (OPT) is a biotechnology company focused on developing treatments for eye diseases. The company operates primarily in the healthcare sector, with its core product being OPT-302, a novel therapy intended for the treatment of wet age-related macular degeneration (wet AMD) and other retinal vascular disorders. Opthea's mission is to enhance vision care by pioneering innovative therapies that address unmet medical needs in ophthalmology.